HIV-associated pulmonary arterial hypertension: improving survival despite persistent treatment gaps - a systematic review and meta-analysis.

AIDSOct 1, 2026 (epub)
Clinical ResearchInfectious DiseasesPulmonology

Marcos Vinicius Fernandes Garcia, Tim Lahm

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined 12 cohorts of patients with HIV-associated pulmonary arterial hypertension (HIV-PAH), totaling 537 individuals. The study found that while survival rates improved over three decades, only 64% of patients received targeted therapy at diagnosis, indicating significant treatment gaps in this population.

Key findings

  • HIV-PAH patients exhibited severe hemodynamics and advanced functional limitations.
  • Only 64% of patients received PAH-targeted therapy at diagnosis.
  • Survival rates improved progressively over three decades with increased therapy use.

Why it matters

Understanding the treatment gaps in HIV-PAH is crucial for improving patient outcomes. Enhanced awareness and timely intervention with contemporary therapies could significantly impact survival rates in this vulnerable population.

Source

PubMed · PMID 42826228

Published in AIDS. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.